Media, page-7

Anyone who has questions re anything Immutep should contact Catherine Strong at investor relations. She’s great.

Here is a copy of a reply about a query I had on IMP761 progress( received today)…

”Apologies, I didn’t manage to come back to you earlier. It is very nice to be contacted by a supportive excited shareholder.

IMP761 is an important and promising candidate in the IMM portfolio of four LAG-3 therapies. While we haven’t lodged many recent updates about it via the ASX, preparatory work has been going on behind the scenes to advance it towards the clinic. Immutep has been continuing its GMP manufacturing preparations for IMP761 in recent months and is planning for toxicology studies and other pre-clinical evaluations of the candidate.

There haven’t been any particular hurdles, but the company is always mindful it is operating with limited resources and has to prioritise accordingly.”